Related references
Note: Only part of the references are listed.Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
Vikas A. Gupta et al.
BLOOD (2021)
Targeting epigenetic mechanisms to overcome venetoclax resistance
Gabriel Prado et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2021)
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Shaji K. Kumar et al.
LANCET ONCOLOGY (2020)
Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies
Melissa A. Fischer et al.
BLOOD ADVANCES (2020)
XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis
Zhi-Chuan Zhu et al.
CELL DEATH & DISEASE (2019)
Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
Justin Taylor et al.
CANCER DISCOVERY (2019)
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma
Ujjawal H. Gandhi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1
Daniel A. Luedtke et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Targeting Bcl-2 for the treatment of multiple myeloma
Cyrille Touzeau et al.
LEUKEMIA (2018)
Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
Enyuan Shang et al.
SCIENTIFIC REPORTS (2018)
Pathways and mechanisms of venetoclax resistance
Prithviraj Bose et al.
LEUKEMIA & LYMPHOMA (2017)
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Shaji Kumar et al.
BLOOD (2017)
BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics
C. Touzeau et al.
LEUKEMIA (2016)
Cyclin D1, cancer progression, and opportunities in cancer treatment
Shuo Qie et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose et al.
MOLECULAR CANCER THERAPEUTICS (2016)
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
C. Touzeau et al.
LEUKEMIA (2014)
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
Y-T Tai et al.
LEUKEMIA (2014)
A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma
Elena Beltran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Cyclin D as a therapeutic target in cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2011)
The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention
John P. Alao
MOLECULAR CANCER (2007)
Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels
K Specht et al.
BLOOD (2004)
C-terminal sequences direct cyclin D1-CRM1 binding
S Benzeno et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients
R Fonseca et al.
BLOOD (2002)
Bcl-2 induces cyclin D-1 promoter activity in human breast epithelial cells independent of cell anchorage
HM Lin et al.
CELL DEATH AND DIFFERENTIATION (2001)
Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation
JR Alt et al.
GENES & DEVELOPMENT (2000)
Share Paper
